GLP-1 Programs · Physician-Governed
A hybrid program for obesity and Type 2 diabetes. Your clinicians prescribe and govern; Lillia runs the coaching, monitoring and follow-up around them, configured to how your clinic already works. Fewer patients fall off treatment, and every outcome is documented and reportable.
How the partnership works
Your clinicians prescribe and govern. Lillia runs the program around them.
Your physicians hold every clinical decision. The patient app and your care portal are two faces of one platform, on a shared record, and the agents run the day to day. Switch sides to see it from each seat.
One message on the phone. The orchestrator routes it to every agent working on it. Hover any message, or any agent.
The portal runs the program in the background. Pick a view.
A registry of voice agents, including a GLP-1 Reminder Agent for adherence and side-effect reminders, plugged into the GLP-1 journey.
Drafted by an AI assistant, then reviewed and approved by the practitioner before anything reaches the patient.
Clinical decisions stay with the treating physician, and anything flagged routes to a named human immediately.
Every agent interaction and call is logged, reviewable and reportable, so the work is provable to any payer.
Why the outcomes hold up
The same platform is a measurement engine.
Everything the app and your care team capture is written to one shared record that syncs with your EMR or EHR, so your clinicians and ours always work from the same data.
Every patient follows a defined 12-month pathway with set consultations and checkpoints, so outcomes stay comparable across a cohort.
Labs, smart-scale and CGM data, and structured check-ins all feed the one shared record.
Our published models forecast glucose and HbA1c from adherence data, flagging who needs attention before results slip. Published in ADA 2026 ↗
The programs
Two programs: Obesity and Type 2 diabetes.
The figures below are Lillia's recommended targets, built from the ADA 2026 Standards of Care and our published research. This is our version of the program; we adapt the targets, the journey and the cadence to your clinic's protocols.
GLP-1 powered obesity management, tracked by smart-scale body composition, not weight alone.
Our recommended targets based on ADA 2026, adapted to your protocols
Smart scale · Muscle-sparing focus · Relapse prevention
Measurable improvement in associated comorbidities: blood pressure, lipids and metabolic health.
GLP-1 powered Type 2 diabetes management, with continuous glucose monitoring guiding safe titration.
Our recommended targets based on ADA 2026, adapted to your protocols
CGM guided · Hypoglycemia protection · Digital-twin insight
Measurable improvement in associated comorbidities: blood pressure, lipids and cardiovascular risk.
How it runs
Side effects, adherence and monitoring.
Starting the medicine is easy. Keeping patients on it safely is the real work.
We anticipate and coach patients through nausea and other GI effects from the first dose, the single biggest reason people stop GLP-1 in the early weeks.
Injection reminders, weekly check-ins and a coach on call keep patients on dose and on track between clinic visits.
Symptoms and glucose are tracked continuously, and anything concerning is routed through a structured escalation matrix to the right responder.
The 12-month journey
Two views of the same structured program: the day-by-day journey, and the team that delivers it.
Across the first week: history and eligibility, app onboarding, baseline labs, devices dispatched, and your physician's prescription.
Smart scale, and CGM for diabetes, set up with guided support. The journey clock starts here.
First injection with a coach on video, the full multidisciplinary consult, and the first diet and exercise plans.
Nutritionist reviews scale and vitals against food and activity logs; the plan is updated.
Multidisciplinary review; your physician assesses response and side effects and adjusts the dose.
Repeat bloods (HbA1c, lipid profile, liver profile, etc.) collected to measure the response objectively.
Progress review, prescription confirmed, and a formal transition into the sustenance phase.
Consultation frequency tapers while monitoring continues. Repeat lab tests as indicated, quarterly and at the end of the program, with physician-led dose titration through to a planned off-ramp.
Weekly AI check-ins and injection reminders run continuously between these milestones, catching barriers and new symptoms early, before they turn into drop-offs.
One-to-one, plus weekly check-ins and continuous device monitoring. Every touchpoint is scheduled, not left to chance.
Then through the sustenance phase (Months 4 to 12): monthly consultations with experts, with weekly check-ins by the health coach.
Safety & governance
Set with your clinical team.
Escalation thresholds, red-flag routing and who gets called are co-defined with your clinicians. The clinical essentials:
On the numbers. Targets align to the ADA 2026 Standards of Care and reflect landmark trials: SURMOUNT-2 recorded 9.6 to 11.6% additional weight loss with Tirzepatide, and STEP 2 recorded 6.2% with Semaglutide 2.4 mg. They are design targets, measured against each cohort in delivery.
In-app education
Patients stay on therapy when they understand it.
A plain-language, physician-approved library unlocks step by step through the journey, turning the moments that usually cause drop-off into moments patients are ready for.
Our published research
Peer-reviewed in chronic care and diabetes.
Lillia's published research is in digital chronic-care and diabetes, in journals including the American Diabetes Association's Diabetes and Elsevier. We do not yet publish GLP-1 cohort outcomes; this is the measurement rigour we bring to the GLP-1 program.
Hover to pause, and tap any card to open the abstract. Published under Lillia’s former name, Droobi.
Let's build it together
Tell us who you serve, whether a clinic network, an insured population, or a therapy you want to support, and we will shape the program, the targets and the reporting around it.